Literature DB >> 7795224

Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets.

Y Yatomi1, F Ruan, S Hakomori, Y Igarashi.   

Abstract

Sphingosine-1-phosphate (Sph-1-P) is the initial product of catabolism of sphingosine by sphingosine kinase and is cleaved by Sph-1-P lyase to a fatty aldehyde and ethanolamine phosphate. This phosphorylated sphingoid base is not only an intermediary catabolite, but also a bioactive lipid with important functions, including stimulation of cell proliferation in Swiss 3T3 fibroblasts and inhibition of tumor cell motility. In the present study, we examined functional roles of Sph-1-P in human platelets. Sph-1-P induced platelet shape change and aggregation reactions, although it failed to elicit secretion. Sphingosine, ceramide, sphingomyelin, and N,N-dimethylsphingosine did not mimic the positive effects of Sph-1-P on platelets. Subthreshold concentrations of Sph-1-P and weak platelet agonists such as adenosine diphosphate (ADP) and epinephrine synergistically elicited aggregation, which may be important for efficient amplification of platelet activation. Sph-1-P induced intracellular Ca2+ mobilization and the dose-response for Ca2+ release correlated closely with the concentration required for induction of shape change. On addition of [3H]sphingosine to intact platelets, the label was rapidly converted to Sph-1-P, and subsequently to ceramide and sphingomyelin. Interestingly, the Sph-1-P formed was specifically released into medium on stimulation of platelets with physiologic agonists. The amount of Sph-1-P in platelets, as measured by its conversion into radiolabeled N-acetyl-Sph-1-P, was 1.4 nmol/10(9) cells and was about four times higher than the mass of Sph present. When compared by mole percent Sph-1-P/phospholipid, the value for platelets is over 10 times higher than that for neutrophils. Our results suggest that Sph-1-P, rapidly converted from sphingosine, abundantly stored in platelets, and released on the cell activation, may play a physiologic role in thrombosis, hemostasis, and the natural wound-healing processes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795224

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  99 in total

1.  Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3.

Authors:  H Okamoto; N Takuwa; T Yokomizo; N Sugimoto; S Sakurada; H Shigematsu; Y Takuwa
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Sphingosine 1-phosphate-induced vasoconstriction is elevated in mesenteric resistance arteries from aged female rats.

Authors:  D G Hemmings; Y Xu; S T Davidge
Journal:  Br J Pharmacol       Date:  2004-08-23       Impact factor: 8.739

3.  Granule-mediated release of sphingosine-1-phosphate by activated platelets.

Authors:  Deepa Jonnalagadda; Manjula Sunkara; Andrew J Morris; Sidney W Whiteheart
Journal:  Biochim Biophys Acta       Date:  2014-08-23

4.  Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors:  Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

Review 5.  Regulation of vascular physiology and pathology by the S1P2 receptor subtype.

Authors:  Athanasia Skoura; Timothy Hla
Journal:  Cardiovasc Res       Date:  2009-03-15       Impact factor: 10.787

6.  Sphingosine-1-phosphate signaling regulates lamellipodia localization of cortactin complexes in endothelial cells.

Authors:  Jen-Fu Lee; Harunobu Ozaki; Xi Zhan; Eugenia Wang; Timothy Hla; Menq-Jer Lee
Journal:  Histochem Cell Biol       Date:  2006-01-14       Impact factor: 4.304

7.  Characterization of sphingomyelinase activity released by thrombin-stimulated platelets.

Authors:  E Romiti; V Vasta; E Meacci; M Farnararo; T Linke; K Ferlinz; K Sandhoff; P Bruni
Journal:  Mol Cell Biochem       Date:  2000-02       Impact factor: 3.396

Review 8.  Sphingolipids in inflammation: pathological implications and potential therapeutic targets.

Authors:  Graeme F Nixon
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

9.  Evidence for the presence of multiple forms of Sph kinase in human platelets.

Authors:  Y Banno; M Kato; A Hara; Y Nozawa
Journal:  Biochem J       Date:  1998-10-15       Impact factor: 3.857

10.  Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid.

Authors:  L L Cooling; K E Walker; T Gille; T A Koerner
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.